Breaking News Instant updates and real-time market news.

CNC

Centene

$96.81

5.9336 (6.53%)

, JWN

Nordstrom

$47.74

2.69 (5.97%)

12:15
09/13/17
09/13
12:15
09/13/17
12:15

On The Fly: Top stock stories at midday

Stocks began the session with minor losses and have remained very close to the flatline throughout the morning, with the averages in a virtual holding pattern and trading ranges extremely narrow. The market has held up well after closing yesterday at record highs and facing a headwind in Apple (AAPL) shares, which are struggling following yesterday's iPhone X unveiling. ECONOMIC EVENTS: In the U.S., the producer-price index rose 0.2% in August with the core rate up 0.1%, both of which were a bit below expectations. In Asia, Japan's PPI grew 2.9% year-over-year in August, representing its highest growth level since 2008. COMPANY NEWS: Shares of Centene (CNC) advanced nearly 7% after the health insurer announced last night a "highly accretive" acquisition of Fidelis Care for $3.75B. As other healthcare insurers like Aetna (AET), Anthem (ANTM) and UnitedHealth (UNH) step back from the Affordable Care Act's challenged insurance exchanges, Centene, which specializes in the state and federal Medicaid programs for less advantaged and underserved, continues to execute on the ACA's public insurance exchange. Following the Fidelis deal, Centene will now have "leadership" position in the country's four largest managed care states by membership - California, Florida, New York and Texas. MAJOR MOVERS: Among the notable gainers was Nordstrom (JWN), which rose 6% after CNBC reported that the family that controls the department store chain is close to a deal to choose private equity firm Leonard Green & Partners to help fund a "go private" deal. Also higher was Target (TGT), whose shares climbed 3% in early trading after the company announced that it will hire significantly more seasonal workers for the critical holiday season than last year. Among the noteworthy losers was Western Digital (WDC), which dropped 4% after joint-venture partner Toshiba (TOSYY) said it has entered into a memorandum of understanding with a consortium lead by Bain Capital memorializing the parties' intent to negotiate a definitive agreement for the sale of Toshiba Memory Corporation by the end of this month. Also lower was Lexicon Pharmaceuticals (LXRX), which fell 9% after the company's Phase 3 inTandem3 study results were published in the New England Journal of Medicine, accompanied by an editorial that JPMorgan analyst Jessica Fye said "reads cautiously" on associated diabetic ketoacidosis. INDEXES: Near midday, the Dow was up 2.93, or 0.01%, to 22,121.79, the Nasdaq was down 6.24, or 0.1%, to 6,448.04, and the S&P 500 was down 1.38, or 0.06%, to 2,495.10.

CNC

Centene

$96.81

5.9336 (6.53%)

JWN

Nordstrom

$47.74

2.69 (5.97%)

AET

Aetna

$162.75

-0.08 (-0.05%)

ANTM

Anthem

$189.43

0.19 (0.10%)

UNH

UnitedHealth

$198.54

1.07 (0.54%)

TGT

Target

$59.56

1.6735 (2.89%)

WDC

Western Digital

$88.78

1.4 (1.60%)

LXRX

Lexicon

$14.74

0.13 (0.89%)

  • 13

    Sep

  • 13

    Sep

  • 14

    Sep

  • 19

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 24

    Oct

CNC Centene
$96.81

5.9336 (6.53%)

09/13/17
CANT
09/13/17
NO CHANGE
Target $107
CANT
Overweight
Centene price target raised to $107 from $100 at Cantor
Cantor Fitzgerald analyst Steven Halper raised his price target for Centene shares to $107 following the company's acquisition of Fidelis Care. The analyst views the acquisition positively, both from a strategic and financial perspective. He keeps an Overweight rating on Centene.
09/13/17
MSCO
09/13/17
NO CHANGE
Target $94
MSCO
Overweight
Deal for Fidelis 'in Centene's wheelhouse,' says Morgan Stanley
Morgan Stanley analyst Zack Sopcak sees Fidelis Care as a strong fit, both culturally and in terms of business mix, for Centene, calling the acquisition a deal "in Centene's wheelhouse." The analyst, who views the downside to the deal as limited given what he sees as modest synergy targets, keeps an Overweight rating and $94 price target on Centene shares.
07/26/17
PIPR
07/26/17
NO CHANGE
Target $105
PIPR
Overweight
Piper says double down on Centene, ups target to $105
Piper Jaffray analyst Sarah James attributes yesterday's post-earnings pullback in shares of Centene to the macro backdrop and the company's spending bump that she believes fuels the bear concern that constant spending for growth pressures margins. The analyst "strongly" disagrees and believe this is when investors should double down on Centene shares. The company will see the greatest multiple expansion in the group and has the highest potential for earnings upside, James tells investors in a research note. She raised her price target for the shares to $105 from $85 and keeps an Overweight rating on the name.
09/13/17
LEER
09/13/17
NO CHANGE
Target $90
LEER
Market Perform
Centene price target raised to $90 from $78 at Leerink
Leerink analyst Ana Gupte raised her price target for Centene to $90 from $78 as she is positive on it after the announcement of the Fidelis AMC acquisition. The analyst reiterates a Market Perform rating on the shares.
JWN Nordstrom
$47.74

2.69 (5.97%)

06/21/17
GDHS
06/21/17
NO CHANGE
GDHS
Nike-Amazon pact yet another department store headwind, says Gordon Haskett
Gordon Haskett analyst noted the reports of Nike (NKE) nearing a deal to sell directly on Amazon (AMZN), which he said wouldn't impact trends overnight but would represent another headwind for department stores, particularly J.C. Penney (JCP) and Kohl's (KSS), where the brand has a larger penetration than at Macy's (M) and Nordstrom (JWN). He keeps an Accumulate rating on Nordstrom, a Hold rating on Macy's and Reduce rating on both J.C. Penney and Kohl's.
09/13/17
09/13/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ON Semiconductor (ON) downgraded to Neutral from Buy at Goldman Sachs with analyst Mark Delaney citing the stock's relative outperformance and lack of catalysts over the next year. 2. Nordstrom (JWN) downgraded to Hold from Accumulate at Gordon Haskett. 3. Mallinckrodt (MNK) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying Mallinckrodt consists of a gradually declining generics portfolio, and a "basket" of branded assets that face some degree of competition and downside risks. 4. Whiting Petroleum (WLL) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Drew Venker citing weak risk-reward relative to peers. 5. GasLog (GLOG) downgraded to Hold from Buy at DNB Markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/17
GDHS
09/13/17
DOWNGRADE
GDHS
Hold
Nordstrom downgraded to Hold from Accumulate at Gordon Haskett
07/14/17
JPMS
07/14/17
NO CHANGE
JPMS
Underweight
JPMorgan keeps Underweight on Nordstrom after management meetings
JPMorgan analyst Matthew Boss keeps an Underweight rating on Nordstrom (JWN) after meeting management at the company's headquarters. Management would not comment on their evaluation of strategic alternatives and the meeting was reshuffled to exclude members of the Nordstrom family while incoming CFO Anne Bramman attended but did not actively participate, Boss tells investors in a research note. The analyst views the company's EBITDA roadmap as "increasingly uncertain" with a greater emphasis on fashion to differentiate mix versus Amazon.com (AMZN) and rising costs of customer acquisition. He believes the retailer's fundamental multi-year risk profile is elevated.
AET Aetna
$162.75

-0.08 (-0.05%)

09/12/17
ARGS
09/12/17
NO CHANGE
ARGS
Aetna price target raised to $185 from $165 at Argus
Argus analyst David Toung believes that Aetna reported "strong" Q2 results. The analyst remains upbeat on the company's 2H17 outlook and keeps a Buy rating on the shares.
07/14/17
PIPR
07/14/17
NO CHANGE
Target $18
PIPR
Overweight
Piper views updated Aetna policy as disappointing for Natera
Piper Jaffray analyst William Quirk views Aetna's (AET) updated non-invasive prenatal testing medical policy, where it decided to continue covering the test only in high risk, as "disappointing." Upside for Natera (NTRA) in the second half of 2017 now falls on Medicaid and microdeletion reimbursement progress, and less so commercial payers flipping to cover average risk, Quick tells investors in a research note. He keeps an Overweight rating on Natera shares with an $18 price target.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $165
FBCO
Outperform
Aetna price target raised to $165 from $160 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Aetna to $165 from $160 ahead of Q2 results. He reiterates an Outperform rating on the shares.
06/28/17
06/28/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altaba (AABA) initiated with an Overweight at JPMorgan. 2. Aetna (AET) and Humana (HUM) were initiated with a Buy at Citi. The firm also added Aetna to its Focus List. 3. CVS Health (CVS) and Walgreens Boots Alliance (WBA) were initiated with a Hold at Needham. 4. Oaktree Capital (OAK) initiated with a Hold at Jefferies. 5. General Motors (GM) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ANTM Anthem
$189.43

0.19 (0.10%)

07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
06/28/17
SBSH
06/28/17
NO CHANGE
Target $205
SBSH
Buy
Anthem removed from Focus List at Citi
Citi analyst Ralph Giacobbe removed Anthem (ANTM) from his firm's Focus List but keeps a Buy rating on the shares with a $205 price target. The analyst believes some of the upside catalysts have played out. He also added Aetna (AET) to the Focus List.
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
UNH UnitedHealth
$198.54

1.07 (0.54%)

08/30/17
ADAM
08/30/17
DOWNGRADE
Target $54
ADAM
Hold
The Advisory Board downgraded to Hold from Buy at Canaccord
Canaccord analyst Richard Close downgraded The Advisory Board (ABCO) to Hold from Buy based on the announced transaction to split the company by selling the Healthcare business to UnitedHealth's (UNH) Optum unit and the Education Business to Vista Equity Partners. Close lowered his price target to $54.29 on Advisory Board shares.
08/11/17
COWN
08/11/17
NO CHANGE
Target $220
COWN
Outperform
UnitedHealth price target raised to $220 from $175 at Cowen
Cowen analyst Christine Arnold raised her price target on UnitedHealth to $220 from $175. The analyst believes the company can achieve its long-term growth targets in 2018, citing Medicare Advantage enrollment growth, operating efficiencies, commercial market penetration, and OptumRx and OptumInsight earnings gains. Arnold reiterated her Outperform rating on UnitedHealth shares.
08/16/17
PIPR
08/16/17
NO CHANGE
PIPR
Overweight
UnitedHealth made 'solid choice' in new CEO, says Piper Jaffray
Piper Jaffray analyst Sarah James views UnitedHealth's promotion of David Wichmann as a "solid choice and not a surprise." The analyst expects business as usual for the company as it continues to push into technology including artificial intelligence. She has an Overweight rating on the shares.
08/29/17
PIPR
08/29/17
NO CHANGE
Target $54.29
PIPR
Neutral
Piper says Advisory Board deal should be marginally accretive to UnitedHealth
Piper Jaffray analyst Sean Wieland said Advisory Board's (ABCO) deal to merge its healthcare business with United Healthcare's (UNH) OptumInsights should be marginally accretive to UnitedHealth and add to his confidence in his FY18 OptumInsights growth estimates. He keeps a Neutral rating on Advisory Board shares and raised his price target on the stock to $54.29 from $51 to reflect the combined estimated amount being paid to shareholders by Optum and Vista Equity, the buyers of Advisory's education business.
TGT Target
$59.56

1.6735 (2.89%)

09/11/17
BERN
09/11/17
NO CHANGE
Target $68
BERN
Outperform
Target everyday low pricing move not surprising, says Bernstein
Bernstein analyst Brandon Fletcher notes that Target announced that it is lowering prices on thousands of consumables items, and its stock is "unsurprisingly" down on the news. It really should not be, Fletcher said, adding that Target had previously announced the move at a recent financial community meeting where management commented on its price investment strategy as, "We've got to make sure that we move from a promotional cadence back to our traditional everyday low price." The analyst reiterates an Outperform rating and $68 price target on the shares.
08/25/17
08/25/17
NO CHANGE

Price cuts not a 'silver bullet' for Amazon to disrupt grocery, says Citi
Citi analyst Alvin Concepcion noted that a number of food retail stocks sold off yesterday after Amazon (AMZN) announced price reductions on certain top selling items at Whole Foods (WFM) stores beginning on Monday when their deal closes, but he contends "price cuts alone are not a silver bullet to becoming a disruptive threat" in an industry that already has many discount operators. He adds that he would be wary of a more significant negative overreaction to news around Amazon's price plans at Whole Foods at this time. Some of the food retailing stocks that declined yesterday included Wal-Mart (WMT), Target (TGT), Kroger (KR), Sprouts Farmers Market (SFM), Costco (COST) and Supervalu (SVU).
08/22/17
JEFF
08/22/17
NO CHANGE
JEFF
Weak spending from Hispanic consumers likely temporary, says Jefferies
A team of Jefferies analysts note that several consumer companies have flagged weakness from Hispanic consumers during this earnings season, which they attribute to likely being linked to uncertainty around immigration policy more than a result of a deteriorating economic backdrop. Companies that have been hurt may be due for a rebound as this is assumed to be a short term phenomenon and some have already noted improvement, the team tells investors. Some of the companies that recently have specifically flagged weakness in Hispanic spending include Foot Locker (FL), Murphy USA (MUSA), O'Reilly Automotive (ORLY), Target (TGT), Valvoline (VVV) and Wingstop (WING), the firm noted.
08/17/17
BWSF
08/17/17
NO CHANGE
Target $14
BWSF
Strong Buy
Barnes & Noble Education 'a weapon' as retailers take on Amazon, says BWS
Barnes & Noble Education (BNED) has become "a weapon" in the fight between traditional brick and mortar retailers and Amazon (AMZN), BWS Financial analyst Vahid Khorsand tells investors in an intraday research note. Target's (TGT) partnership with Barnes & Noble Education to deliver college essentials directly to students "has so far gone unappreciated by the market," the analyst contends. He believes Barnes & Noble Education's earnings report on August 30 could serve as a catalyst for the stock on "multiple fronts." Khorsand has a Buy rating on the name with a $14 price target.
WDC Western Digital
$88.78

1.4 (1.60%)

09/12/17
RBCM
09/12/17
NO CHANGE
RBCM
Western Digital likely to hold minority stake in Toshiba, says RBC Capital
After Japanese newspaper Nikkan reported that a consortium which includes Western Digital (WDC) would buy Toshiba's (TOSBF) memory assets, RBC Capital analyst Amit Daryanani says that Western Digital will likely hold a minority stake in the assets, given anti-trust concerns. The analyst estimates that a 12%-13% stake would boost Western Digital's EPS by 25c-30c in 2018. Daryanani believes that the deal will be positive for the company as it will enable it to secure NAND bit capacity, prevent Foxconn/SK Hynix from getting the asset, and could boost its profits. He keeps a $115 price target and an Outperform rating on the stock.
09/13/17
SBSH
09/13/17
NO CHANGE
Target $110
SBSH
Buy
Citi still sees Western Digital participating in Toshiba joint venture
Citi analyst Stanley Kovler says he continues to believe Western Digital (WDC) will be able to participate in the joint venture with Toshiba (TOSYY, TOSBF) and source NAND much like it has in the past, even after Toshiba signed a memorandum of understanding with the Bain Capital consortium for the sale of its memory business. If Western Digital takes a more commercial approach to resolution versus a legal route, the analyst sees a path to work with Bain and co-invest in Fab6. Kovler keeps a Buy rating on Western Digital with a $110 price target.
09/13/17
LBOW
09/13/17
NO CHANGE
Target $120
LBOW
Buy
iPhone 64GB starting point a 'pleasant surprise' for NAND makers, says Longbow
Longbow analyst Joe Wittine said many had expected a 32GB starting point for the memory in the new iPhones, consistent with the 7/7+, calling the new 64GB starting point for the iPhone 8/8+ a "pleasant surprise" for companies in the NAND supply chain. Rising NAND consumption could help smooth the eventual downside of the cycle for Western Digital, helping it maintain greater than 40% gross margins for longer, added the analyst. Wittine keeps a Buy rating and $120 price target on Western Digital shares.
09/11/17
JEFF
09/11/17
DOWNGRADE
JEFF
Hold
Seagate downgraded to Hold from Buy at Jefferies
Jefferies analyst James Kisner downgraded Seagate Technology (STX) to Hold after his channel checks indicated the company may still be struggling with the ramp of its 10TB helium drives. The analyst is also hearing about about potential increased price competition in nearline. He cut his price target for Seagate shares to $29 from $40. Kisner maintains a Hold rating on Seagate peer Western Digital (WDC).
LXRX Lexicon
$14.74

0.13 (0.89%)

09/13/17
JPMS
09/13/17
NO CHANGE
JPMS
Neutral
Editorial published with Lexicon data reads cautiously, says JPMorgan
JPMorgan analyst Jessica Fye noted that full results for Lexicon Pharmaceuticals' Phase 3 inTandem3 study were released in the New England Journal of Medicine, accompanied by an editorial that reads cautiously on associated diabetic ketoacidosis. The comments from the editorial give her further pause on overall DKA risk and she thinks the relative risk in pumps patients may be at a threshold where physicians and the FDA could be cautious, she tells investors. Fye keeps a Neutral rating on Lexicon shares, which have fallen by more than 9% following the publication.
03/07/17
SBSH
03/07/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon price target raised to $28 from $24 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $28 saying the company's potential in diabetes remains underappreciated. Management's commentary on sotagliflozin should re-assure investors who remain unconvinced about the T1D thesis, Nochomovitz tells investors in a post-earnings research note. He keeps a Buy rating on Lexicon.
03/01/17
WEDB
03/01/17
NO CHANGE
WEDB
Lexicon price target raised to $38 from $33 at Wedbush
Wedbush analyst Liana Moussatos increased her price target on Lexicon after the FDA approved Lexicon's lead drug, Zermelo, for carcinoid syndrome. The analyst thinks that the company has several additional upcoming positive potential catalysts. She keeps an Outperform rating on the stock.
12/22/16
SBSH
12/22/16
NO CHANGE
Target $24
SBSH
Buy
Citi disagrees with market view on Lexicon Pharmaceuticals
After shares of Lexicon Pharmaceuticals fell 7% yesterday following data from the second Phase 3 testing sotagliflozin in Type 1 diabetes, Citi analyst Yigal Nochomovitz says he disagrees with the market view. Investors are "getting too bogged" down on the safety question, the analyst tells investors in a research note. The data "unambiguously solve a major clinical challenge" in Type 1, which is getting A1c lower without the expense of glycemic excursions and thus more hypos, Nochomovitz writes. He keeps a Buy rating on Lexicon with a $24 price target.

TODAY'S FREE FLY STORIES

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary  »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ITEK

Inotek Pharmaceuticals

17:04
01/19/18
01/19
17:04
01/19/18
17:04
Hot Stocks
Boxer Capital reports 5.3% passive stake in Rocket Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$32.80

0.35 (1.08%)

17:03
01/19/18
01/19
17:03
01/19/18
17:03
Syndicate
Breaking Syndicate news story on Oil States »

Oil States files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

, QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

16:43
01/19/18
01/19
16:43
01/19/18
16:43
Hot Stocks
Broadcom receives second request from FTC for proposed Qualcomm deal »

Broadcom (AVGO) announced…

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRNC

tronc

$19.53

0.3 (1.56%)

16:37
01/19/18
01/19
16:37
01/19/18
16:37
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, WSJ says »

Ross Levinsohn, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AP

Ampco-Pittsburgh

$14.20

0.15 (1.07%)

16:35
01/19/18
01/19
16:35
01/19/18
16:35
Syndicate
Breaking Syndicate news story on Ampco-Pittsburgh »

Ampco-Pittsburgh files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

, UBSH

Union Bankshares

$38.79

0.54 (1.41%)

16:33
01/19/18
01/19
16:33
01/19/18
16:33
Hot Stocks
Carlyle Group reports 6% passive stake in Union Bankshares »

In a regulatory filing,…

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

UBSH

Union Bankshares

$38.79

0.54 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

16:31
01/19/18
01/19
16:31
01/19/18
16:31
Hot Stocks
Andeavor Logistics raises quarterly cash distribution to $1.00 per unit »

The fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

16:30
01/19/18
01/19
16:30
01/19/18
16:30
Options
Preliminary option volume of 22.8M today »

Preliminary option volume…

TRNC

tronc

$19.53

0.3 (1.56%)

16:26
01/19/18
01/19
16:26
01/19/18
16:26
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, DJ says »

Dow Jones added that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RKDA

Arcadia Biosciences

$0.27

0.0285 (11.88%)

16:25
01/19/18
01/19
16:25
01/19/18
16:25
Conference/Events
Arcadia Biosciences to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.